{"id":67223,"date":"2026-06-03T19:25:55","date_gmt":"2026-06-03T11:25:55","guid":{"rendered":"https:\/\/flcube.com\/?p=67223"},"modified":"2026-06-03T19:25:56","modified_gmt":"2026-06-03T11:25:56","slug":"xtalpi-backed-signet-therapeutics-secures-fda-ind-approval-for-worlds-first-pan-tead-inhibitor-sigx2649-ahead-of-schedule","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67223","title":{"rendered":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#8217;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Signet Therapeutics<\/strong>, an AI-driven biotechnology company incubated by <strong>Xtalpi Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a>), announced it has received <strong>Investigational New Drug (IND) approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong>\u2014<strong>ahead of schedule<\/strong>\u2014for <strong>SIGX2649<\/strong>, the <strong>world&#8217;s first pan-TEAD inhibitor<\/strong> targeting all four subtypes of the TEAD transcription factor family.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This milestone represents the <strong>second innovative pipeline<\/strong> from the Xtalpi-Signet collaboration to advance to clinical trials, following SIGX1094 (the world&#8217;s first targeted therapy for diffuse gastric cancer), further validating their proprietary <strong>&#8220;AI + organoid&#8221; drug discovery strategy<\/strong> in the competitive oncology landscape.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parent Company<\/strong><\/td><td>Xtalpi Inc. (HKG: 2228)<\/td><\/tr><tr><td><strong>Operating Subsidiary<\/strong><\/td><td>Signet Therapeutics<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td><strong>Timeline Achievement<\/strong><\/td><td>Approved ahead of schedule<\/td><\/tr><tr><td><strong>Product Name<\/strong><\/td><td>SIGX2649<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Pan-TEAD inhibitor (Hippo pathway modulator)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical completed, clinical trials authorized<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-novel-therapeutic-mechanism\" class=\"wp-block-heading\">Novel Therapeutic Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Family<\/strong>: TEAD transcription factors (all four subtypes: TEAD1, TEAD2, TEAD3, TEAD4)<\/li>\n\n\n\n<li><strong>Pathway<\/strong>: Hippo signaling pathway\u2014a key regulator of organ size, cell proliferation, and tumorigenesis<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First-in-class pan-TEAD inhibitor with comprehensive coverage across all TEAD family members<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Dysregulated Hippo pathway and TEAD overexpression are implicated in multiple solid tumors<\/li>\n\n\n\n<li><strong>Market Potential<\/strong>: Broad applicability across solid tumor types with unmet therapeutic needs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-pipeline-progression\" class=\"wp-block-heading\">Strategic Pipeline Progression<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pipeline Asset<\/th><th>Indication<\/th><th>Development Status<\/th><th>Innovation Claim<\/th><\/tr><\/thead><tbody><tr><td><strong>SIGX1094<\/strong><\/td><td>Diffuse gastric cancer<\/td><td>Clinical trials initiated<\/td><td>World&#8217;s first targeted therapy for indication<\/td><\/tr><tr><td><strong>SIGX2649<\/strong><\/td><td>Solid tumors (pan-TEAD)<\/td><td>FDA IND approved<\/td><td>World&#8217;s first pan-TEAD inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-ai-organoid-drug-discovery-platform-validation\" class=\"wp-block-heading\">&#8220;AI + Organoid&#8221; Drug Discovery Platform Validation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Integration<\/strong>: Combines Xtalpi&#8217;s AI-driven target identification with advanced organoid disease models<\/li>\n\n\n\n<li><strong>Clinical Translation Success<\/strong>: Two distinct first-in-class assets advancing to clinical development<\/li>\n\n\n\n<li><strong>Platform Efficiency<\/strong>: Accelerated IND timeline demonstrates operational excellence<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Proprietary approach enables identification of novel targets and mechanisms<\/li>\n\n\n\n<li><strong>Global Recognition<\/strong>: FDA approval validates platform&#8217;s ability to generate clinically relevant candidates<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-xtalpi\" class=\"wp-block-heading\">Strategic Implications for Xtalpi<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Biology Leadership<\/strong>: Reinforces Xtalpi&#8217;s position at forefront of AI-driven drug discovery<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Expands beyond single asset dependency with multiple clinical-stage programs<\/li>\n\n\n\n<li><strong>Global Ambitions<\/strong>: U.S. regulatory approval facilitates international development and partnership opportunities<\/li>\n\n\n\n<li><strong>Investor Confidence<\/strong>: Accelerated timelines and first-in-class assets support premium valuation<\/li>\n\n\n\n<li><strong>Ecosystem Development<\/strong>: Signet Therapeutics success validates Xtalpi&#8217;s company incubation model<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-analysis\" class=\"wp-block-heading\">Market Impact Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Validation<\/strong>: TEAD family represents emerging high-value target class in oncology<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: First-mover advantage in pan-TEAD inhibition with no direct competitors<\/li>\n\n\n\n<li><strong>Therapeutic Breadth<\/strong>: Potential applications across multiple solid tumor indications including lung, breast, and gastrointestinal cancers<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Large addressable market given Hippo pathway involvement in diverse malignancies<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Strong platform validation may attract major pharmaceutical partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-considerations\" class=\"wp-block-heading\">Commercial Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Premium<\/strong>: First-in-class status and novel mechanism support premium pricing strategy<\/li>\n\n\n\n<li><strong>Development Strategy<\/strong>: Likely focus on tumor types with highest TEAD dependency and unmet need<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Potential for accelerated approval based on novel mechanism and high unmet need<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: U.S. IND approval provides foundation for international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SIGX2649. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[99,16,62,1112,221,696],"class_list":["post-67223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ai","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-2228","tag-signet-therapeutics","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#039;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world&#039;s first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67223\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#039;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule\" \/>\n<meta property=\"og:description\" content=\"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world&#039;s first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67223\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T11:25:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T11:25:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#8217;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule\",\"datePublished\":\"2026-06-03T11:25:55+00:00\",\"dateModified\":\"2026-06-03T11:25:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223\"},\"wordCount\":539,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0301-1.webp\",\"keywords\":[\"AI\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2228\",\"Signet Therapeutics\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67223#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67223\",\"name\":\"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0301-1.webp\",\"datePublished\":\"2026-06-03T11:25:55+00:00\",\"dateModified\":\"2026-06-03T11:25:56+00:00\",\"description\":\"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world's first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67223\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0301-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0301-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67223#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#8217;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule - Insight, China&#039;s Pharmaceutical Industry","description":"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world's first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67223","og_locale":"en_US","og_type":"article","og_title":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule","og_description":"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world's first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.","og_url":"https:\/\/flcube.com\/?p=67223","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T11:25:55+00:00","article_modified_time":"2026-06-03T11:25:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67223#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67223"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#8217;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule","datePublished":"2026-06-03T11:25:55+00:00","dateModified":"2026-06-03T11:25:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67223"},"wordCount":539,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","keywords":["AI","Cancer","Clinical trial approval \/ initiation","HKG: 2228","Signet Therapeutics","Xtalpi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67223#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67223","url":"https:\/\/flcube.com\/?p=67223","name":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67223#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","datePublished":"2026-06-03T11:25:55+00:00","dateModified":"2026-06-03T11:25:56+00:00","description":"Signet Therapeutics, an AI-driven biotechnology company incubated by Xtalpi Inc. (HKG: 2228), announced it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)\u2014ahead of schedule\u2014for SIGX2649, the world's first pan-TEAD inhibitor targeting all four subtypes of the TEAD transcription factor family.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67223#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67223"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67223#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","width":1080,"height":608,"caption":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World's First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67223#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xtalpi-Backed Signet Therapeutics Secures FDA IND Approval for World&#8217;s First Pan-TEAD Inhibitor SIGX2649 Ahead of Schedule"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0301-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67223"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67223\/revisions"}],"predecessor-version":[{"id":67225,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67223\/revisions\/67225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67224"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}